Analyzing Global Trends of Biomarker use in Drug Interventional Clinical Studies

drug discoveries & therapeutics

Volumn 6, Issue 2, 2013, Pages 102-107

  Hayashi, Kunihiko ^a,b   Masuda, Sachiko ^a   Kimura, Hiromichi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b Office of Pharmaceutical Industry Research   (Japan)

Author keywords

clinical study efficiency; Drug development; industrial policy

Indexed keywords

EID: 85008748716     PISSN: 18817831     EISSN: 1881784x     Source Type: Journal    
DOI: 10.5582/ddt.2012.v6.2.102     Document Type: Article

References (14)

1. Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, Schacht AL. How to improve R&D productivity: The pharmaceutical industry's grand challenge. Nat Rev Drug Discov. 2010; 9:203-214.
2. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: New estimates of drug development costs. J Health Econ. 2003; 22: 151-185.
3. US Department of Health and Human Services, Food and Drug Administration. Critical Path Opportunities List, March 2006. http://www.fda.gov/downloads/ ScienceResearch/SpecialTopics/CriticalPathlnitiative/ CriticalPathOpportunitiesReports/UCM077258.pdf (accessed February 6, 2012).
4. Thiers FA, Sinskey AJ, Berndt ER. Trends in the globalization of clinical trials. Nat Rev Drug Discov. 2008; 7:13-14.
5. WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment 2011. Oslo, 2010.
6. DiMasi JA, Feldman L, Secker A, Wilson A. Trends in risks associated with new drug development: Success rates for investigational drugs. Clin Pharmacol Ther. 2010; 87:272-277.
7. Goulart BHL, Clark JK, Pien HH, Roberts TG, Finkelstein SN, Chabner BA. Trends in the use and role of biomarkers in phase I oncology trials. Clin Cancer Res. 2007; 13:6719-6726.
8. US Department of Health and Human Services, Food and Drug Administration. Guidance for Industry, Qualification Process for Drug Development Tool, October 2010. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ UCM230597.pdf (accessed February 6, 2012).
9. US Department of Health and Human Services, Food and Drug Administration. Draft Guidance for Industry and FDA Staff, In Vitro Companion Diagnostic Devices, July 2011. http://www.fda.gov/downloads/MedicalDevices/ DeviceRegulationandGuidance/GuidanceDocuments/ UCM262327.pdf (accessed February 6, 2012).
10. Yasuda SU, Zhang L, Huang SM. The role of ethnicity in variability in response to drugs: Focus on clinical pharmacology studies. Clin Pharmacol Ther. 2008; 84: 417-423.
11. Tsuji K, Tsutani K. Approval of new drugs 1999-2007: Comparison of the US, the EU and Japan situations. J Clin Pharm Ther. 2010; 35:289-301.
12. US Department of Health and Human Services, Food and Drug Administration. FDA, EMA to Consider Additional Test Results When Assessing New Drug Safety, June 2008. http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/2008/ucm116911.htm (accessed February 6, 2012).
13. Pharmaceuticals and Medical Devices Agency. Record of the Consultation on Pharmacogenomics/Biomarkers, May 2010. http://www.pmda.go.jp/operations/shonin/ info/consult/file/pbm-kiroku-e.pdf (accessed February 6, 2012).
14. De Angelis C, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, Kotzin S, Laine C, Marusic A, Overbeke AJ, Schroeder TV, Sox HC, Van Der Weyden MB. Clinical trial registration: A statement from the International Committee of Medical Journal Editors. N Engl J Med. 2004; 351:1250-1251.